Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 340

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

Open access
Simrén, Joel, Leuzy, Antoine, Karikari, Thomas K., Hye, Abdul, Benedet, Andréa Lessa, Lantero‐Rodriguez, Juan, Mattsson‐Carlgren, Niklas, Schöll, Michael, Mecocci, Patrizia, Vellas, Bruno, Tsolaki, Magda, Kloszewska, Iwona, Soininen, Hilkka, Lovestone, Simon, Aarsland, Dag, for the AddNeuroMed consortium, Hansson, Oskar, Rosa‐Neto, Pedro, Westman, Eric, Blennow, Kaj, Zetterberg, Henrik, Ashton, Nicholas J. · 2021 · Alzheimer's & Dementia

Abstract

Introduction: This study investigated the diagnostic and disease‐monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results: Phosphorylated‐tau181 (P‐tau181), neurofilament light, amyloid‐β (Aβ42/40), Total‐tau and Glial fibrillary acidic protein were altered in AD dementia but P‐tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P‐tau181 was increased in MCI converters compared to non‐converters. Higher P‐tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P‐tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. Discussion: P‐tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P‐tau181 as a non‐invasive and cost‐effective diagnostic and prognostic biomarker in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12283

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 340

Metadata

Authors
Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero‐Rodriguez, J., Mattsson‐Carlgren, N., Schöll, M., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Aarsland, D., for the AddNeuroMed consortium, Hansson, O., Rosa‐Neto, P., Westman, E., Blennow, K., Zetterberg, H., & Ashton, N. J.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-01-25
Volume
17
Issue
7
Pages
1145-1156
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3123207203
Cited by
340
References
60
FWCI
39.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/alz.12283
The paper
Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero‐Rodriguez, J., Mattsson‐Carlgren, N., Schöll, M., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Aarsland, D., for the AddNeuroMed consortium, Hansson, O., Rosa‐Neto, P., Westman, E., . . . Ashton, N. J. (2021). The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12283

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.